Investing.com - Financial Markets Worldwide

UPDATE 2-Pfizer applies for COVID-19 vaccine approval in Japan

Published 2020-12-17, 10:26 p/m

(Adds reported health minister comments)

TOKYO, Dec 18 (Reuters) - Drugmaker Pfizer Inc (NYSE:PFE) PFE.N said on Friday it had applied for approval in Japan for its COVID-19 vaccine, which is already being administered in the United Kingdom and the United States.

The Japanese government has a supply deal with Pfizer for 120 million doses of the vaccine made by the U.S. drugmaker and German partner BioNTech 22UAy.DE .(https:// said in a statement it had made the application to Japan's Health Ministry, along with providing information on tests it has carried out up to now.

A final decision on approval would be made after authorities examine data due in February from Pfizer's trials in Japan, Health Minister Norihisa Tamura was quoted by Jiji News as saying.

Japan has said it wants all its residents vaccinated in the first half of 2021, although Tamura said whether or not to get the vaccine was ultimately up to each individual, Jiji reported.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.